Skip to content
Contact Us
14. DNA helix 3D illustration 14. DNA helix 3D illustration

MassARRAY® Assay Services

Precision for Medicine utilizes MassARRAY® assays to uncover genetic variations and epigenetic modifications with high accuracy and reproducibility

The Agena MassARRAY® system delivers precise, high-throughput solutions for genotyping, somatic mutation detection, and DNA methylation analysis. Precision for Medicine offers MassARRAY® assays either as an individual service or as part of a comprehensive therapeutic development package, which includes biomarker assays and clinical trials.

The_MassARRAY_System_enables_accurate_detection

Precision’s offerings with MassARRAY®

  • Genotyping: Rapidly analyze genetic variants in large populations, ideal for pharmacogenomics, biomarker discovery, and population genetics.
  • Somatic Mutation Detection: Detect low-frequency somatic mutations with high-sensitivity assays, aiding personalized cancer therapy.
  • DNA Methylation Analysis: Conduct accurate methylation studies to explore gene expression regulation, useful in oncology, neurology, and developmental biology.
  • Custom Assays: Develop tailored assays for specific research needs, targeting rare variants or specific mutations with the MassARRAY® platform.

 

Key Benefits

  • Scalability and Efficiency: Supports projects of all sizes, making it versatile and efficient.
  • High Sensitivity and Specificity: Detect low-frequency mutations accurately, ensuring reliable results even with challenging samples.

How Precision leverages the MassARRAY® platform

Precision for Medicine utilizes the MassARRAY® platform to support genetic and epigenetic research. This versatile technology aids in oncology, genetic studies, and pharmacogenetics (PGx), as well as sample integrity verification. Precision offers MassARRAY® assays as standalone services or as part of comprehensive therapeutic development packages.

Oncology

  • Tumor profiling: Identify genetic mutations and epigenetic changes in tumor samples.
  • Therapeutic development: Support the development of targeted therapies by providing detailed genetic and epigenetic data.

Genetic Research

  • Population studies: Analyze genetic variations across different populations.
  • Inherited disorders: Detect genetic mutations associated with inherited diseases.
  • Pharmacogenetics (PGx): Analyze genetic variations that influence individual responses to drugs, aiding in personalized medicine.
  • Copy Number Variation: Detect and analyze variations in the number of copies of a particular gene.

Epigenetic Research

  • Methylation studies: Investigate DNA methylation patterns in various conditions.
  • Gene regulation: Study the impact of epigenetic modifications on gene expression.

Sample analysis workflow

The MassARRAY® technology integrates mass spectrometry with end-point PCR, enabling highly multiplexed reactions under standard cycling conditions. After nucleic acid extraction, Precision processes the samples (typically 10-40 ng) through the following streamlined three-step process.

Agena-Desktop-MassArrayWorkflow Agena-Mobile-MassArrayWorkflow

Related services

  • Explore

    ddPCR

    Advanced ddPCR applications from preclinical to clinical assays including gene therapy viral shedding and CAR-T biodistribution
    Explore
  • Explore

    NGS

    Services including RNA-seq, whole exome sequencing, and targeted DNA/RNA sequencing utilizing both Illumina and Thermo-Fisher NGS platforms
    Explore
  • Explore

    FISH/ISH

    Development of multiplex FISH/ISH assays to detect abnormalities in a range of tissues, including hematological and solid organ tumors
    Explore

Explore related Precision for Medicine blog content

Read our blog to gain more insights and discover work that Precision has supported.

Explore our blog
Read: The Significance of Genomics Analysis in Gene Therapy Development The Significance of Genomics Analysis in Gene Therapy Development

Translational Research - Gene Therapies

The Significance of Genomics Analysis in Gene Therapy Development

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778883, hs_child_table_id=0, hs_updated_at=1715692633893, hs_published_at=1739807653319, description=Jie Yang, PhD is a Scientific Liaison for Precision for Medicine. An Immunologist by training with extensive industry expertise in designing translational assays for biomarker-guided clinical trials. Conducted postdoctoral research on immuno-oncology at MD Anderson Cancer Center. Led biomarker assay development and collaborated on the implementation of new technologies for pre-clinical and clinical studies conducted by pharmaceutical and biotech companies for drug development., avatar=Image{width=885,height=886,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Jie-Yang.png',altText='Jie-Yang',fileId=167372215352}, linkedin=https://www.linkedin.com/in/jie-yang-0528221b, hs_name=, hs_path=, lastname=Yang, hs_initial_published_at=1716212769184, hs_created_at=1709645745114, hs_is_edited=false, hs_deleted_at=0, name=Jie, job=, slug=jie-yang, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Jie Yang avatar

    Jie Yang
Read: Protein Assays: Choosing the Most Effective Method for Biopharmaceutical Development Protein Assays: Choosing the Most Effective Method for Biopharmaceutical Development

Translational Research - Lab Services - Biomarkers

Protein Assays: Choosing the Most Effective Method for Biopharmaceutical Development

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778889, hs_child_table_id=0, hs_updated_at=1714461111815, hs_published_at=1739807653319, description=Travis Harrison, PhD, is Vice President of Diagnostic Development at Precision for Medicine. He brings more than 20 years of bioanalytical assay experience to the Precision team with expertise in ligand-binding and cell-based assays.  Travis has experience supporting clinical and nonclinical studies for a broad range of indications, with an emphasis on diagnostic assays to evaluate immune responses to gene therapies., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Travis%20Harrison.webp',altText='Travis Harrison',fileId=165893006481}, linkedin=https://www.linkedin.com/in/travis-harrison-phd-6108852/, hs_name=, hs_path=, lastname=Harrison, hs_initial_published_at=1716212769184, hs_created_at=1709645745120, hs_is_edited=false, hs_deleted_at=0, name=Travis, job=, slug=travis-harrison, email=, hs_updated_by_user_id=51739740}, second={hs_id=159488778875, hs_child_table_id=0, hs_updated_at=1716454216458, hs_published_at=1739807653319, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475007, name='Precision for Medicine Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1716212769184, hs_created_at=1709645745106, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job= Chief Scientific Officer, slug=deborah-phippard, email=, hs_updated_by_user_id=51739740}, third={}})
  • Travis H. avatar

    Travis H.
  • Deborah P. avatar

    Deborah P.
Read: Guiding Precision Medicine with Liquid Biopsy: Circulating DNA vs Circulating Tumor Cells Liquid Biopsy

Translational Research

Guiding Precision Medicine with Liquid Biopsy: Circulating DNA vs Circulating Tumor Cells

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778878, hs_child_table_id=0, hs_updated_at=1714461171862, hs_published_at=1739807653319, description=Jesus Garcia, PhD, is a tissue and liquid biopsy expert with extensive experience in a wide range of histopathology assays and digital pathology solutions. Part of the implementation of new technologies at MD Anderson Cancer Center in collaboration with immuno-oncology leaders. Currently focused on partnering with biopharma to develop tissue and liquid biopsy biomarker strategies for clinical trials, and to implement digital pathology and AI in the drug development process., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Jesus%20Garcia.webp',altText='Jesus Garcia',fileId=165892429965}, linkedin=https://www.linkedin.com/in/jesusgarciaphd, hs_name=, hs_path=, lastname=Garcia, hs_initial_published_at=1716136551646, hs_created_at=1709645745109, hs_is_edited=false, hs_deleted_at=0, name=Jesus, job=, slug=jesus-garcia, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Jesus Garcia avatar

    Jesus Garcia